VTGN Jan 2026 5.000 put
- Simply Wall St.
Vistagen Therapeutics Full Year 2024 Earnings: EPS Beats Expectations
Vistagen Therapeutics ( NASDAQ:VTGN ) Full Year 2024 Results Key Financial Results Net loss: US$29.4m (loss narrowed by...
- Insider Monkey
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2024 Earnings Call Transcript
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2024 Earnings Call Transcript June 11, 2024 Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year-End 2024 Corporate Update Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. […]
- Business Wire
Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., June 11, 2024--Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year ended March 31, 2024, and provided a corporate update.
